Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 4
1988 3
1989 1
1991 3
1992 5
1993 3
1994 6
1995 4
1996 9
1997 10
1998 14
1999 19
2000 8
2001 15
2002 13
2003 14
2004 11
2005 11
2006 6
2007 9
2008 8
2009 9
2010 8
2011 9
2012 10
2013 5
2014 6
2015 10
2016 5
2017 8
2018 14
2019 17
2020 11
2021 13
2022 2
2023 3
2024 5
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

290 results

Results by year

Filters applied: . Clear all
Page 1
Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R. Yamaguchi M, et al. Among authors: suzumiya j. J Clin Oncol. 2011 Nov 20;29(33):4410-6. doi: 10.1200/JCO.2011.35.6287. Epub 2011 Oct 11. J Clin Oncol. 2011. PMID: 21990393 Clinical Trial.
DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study.
Miyazaki K, Asano N, Yamada T, Miyawaki K, Sakai R, Igarashi T, Nishikori M, Ohata K, Sunami K, Yoshida I, Yamamoto G, Takahashi N, Okamoto M, Yano H, Nishimura Y, Tamaru S, Nishikawa M, Izutsu K, Kinoshita T, Suzumiya J, Ohshima K, Kato K, Katayama N, Yamaguchi M. Miyazaki K, et al. Among authors: suzumiya j. Haematologica. 2020 Sep 1;105(9):2308-2315. doi: 10.3324/haematol.2019.231076. Haematologica. 2020. PMID: 33054055 Free PMC article. Clinical Trial.
Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma.
Kato K, Sugio T, Ikeda T, Yoshitsugu K, Miyazaki K, Suzumiya J, Yamamoto G, Kim SW, Ikegame K, Uehara Y, Mori Y, Ishikawa J, Hiramoto N, Eto T, Nakazawa H, Kobayashi H, Serizawa K, Onizuka M, Fukuda T, Atsuta Y, Suzuki R. Kato K, et al. Among authors: suzumiya j. Bone Marrow Transplant. 2024 Mar;59(3):306-314. doi: 10.1038/s41409-023-02156-4. Epub 2023 Dec 15. Bone Marrow Transplant. 2024. PMID: 38102209
[Hodgkin lymphoma].
Suzumiya J. Suzumiya J. Rinsho Ketsueki. 2009 Apr;50(4):261-70. Rinsho Ketsueki. 2009. PMID: 19404018 Review. Japanese. No abstract available.
End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial.
Kato K, Izutsu K, Nishikori M, Shibayama H, Maeda Y, Yoshimura K, Tateishi U, Miyamoto T, Matsuda Y, Ishikawa J, Rai S, Takahashi T, Yamauchi T, Matsumura I, Akashi K, Kanakura Y, Suzumiya J. Kato K, et al. Among authors: suzumiya j. Int J Hematol. 2024 Jun;119(6):677-685. doi: 10.1007/s12185-024-03738-8. Epub 2024 Mar 22. Int J Hematol. 2024. PMID: 38519820 Clinical Trial.
[Ⅱ.Chronic Lymphocytic Leukemia].
Suzumiya J. Suzumiya J. Gan To Kagaku Ryoho. 2019 May;46(5):868-873. Gan To Kagaku Ryoho. 2019. PMID: 31189806 Japanese. No abstract available.
290 results